The FDA approved Epclusa (fixed-dose combination of sofosbuvir and velpatasvir) to treat adult patients with chronic hepatitis C virus with and without cirrhosis.
A study examined the consequences of an FDA warning recommending against the prescription of the antidepressant citalopram at dosages higher than 40 mg/day.
The FDA has issued a warning of serious and potentially fatal cardiac problems associated with the higher-than-recommended use of the antidiarrheal drug loperamide (Imodium).
Primary care practitioners should be aware of 3 new FDA approvals that may be useful when treating patients with opioid dependence, prostate cancer, and multiple sclerosis.
A safety review showed that when fluoroquinolones were used systemically, they were associated with disabling and potentially permanent serious adverse effects.
The FDA finalized a rule extending its authority to all tobacco products, including e-cigarettes, cigars, hookah tobacco, and pipe tobacco, among others.
The FDA told manufacturers of a drug/device combination to treat schizophrenia they must provide more information before the product can be considered for approval.
